BCL2 and diffuse large B-cell lymphoma: Although information about structural variants were not available for the DLBCL cohort of Lacy et al., information about recurrent mutations was sufficient to assign 36.6% of DLBCLs NOS to a distinct molecular DLBCL cluster in comparison to only 17.4% of our cohort of EBV + DLBCLs for that we also considered genome-wide CNAs and structural variants of BCL2 and BCL6 (p = 0.007, two tailed Fisher exact test).